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Improvement of Endothelial Function
With Dietary Flavanols Is Associated
With Mobilization of Circulating Angiogenic
Cells in Patients With Coronary Artery Disease
Christian Heiss, MD, DRMED,*§ Sarah Jahn, MB,* Melanie Taylor, BS,* Wendy May Real, BS,*
Franca S. Angeli, MD,* Maelene L. Wong, BS,* Nicolas Amabile, MD,* Megha Prasad, BA,*
Tienush Rassaf, MD, DRMED, Javier I. Ottaviani, PHD,§ Shirley Mihardja, PHD,*
Carl L. Keen, PHD,§ Matthew L. Springer, PHD,*†‡ Andrew Boyle, MBBS, PHD,*
William Grossman, MD,* Stanton A. Glantz, PHD,* Hagen Schroeter, PHD,¶
Yerem Yeghiazarians, MD*‡
San Francisco and Davis, California; Düsseldorf, Germany; and McLean, Virginia
Objectives In patients with coronary artery disease (CAD) medically managed according to currently accepted guidelines,
we tested whether a 1-month dietary intervention with flavanol-containing cocoa leads to an improvement of
endothelial dysfunction and whether this is associated with an enhanced number and function of circulating an-
giogenic cells (CACs).
Background Dietary flavanols can improve endothelial dysfunction. The CACs, also termed endothelial progenitor cells, are
critical for vascular repair and maintenance of endothelial function.
Methods In a randomized, controlled, double-masked, cross-over trial, 16 CAD patients (64  3 years of age) received a
dietary high-flavanol intervention (HiFI [375 mg]) and a macronutrient- and micronutrient-matched low-flavanol
intervention (LoFI [9 mg]) twice daily in random order over 30 days.
Results Endothelium-dependent vasomotor function, as measured by flow-mediated vasodilation of the brachial artery,
improved by 47% in the HiFI period compared with the LoFI period. After HiFI, the number of CD34/KDR-
CACs, as measured by flow cytometry, increased 2.2-fold as compared with after LoFI. The CAC functions, as
measured by the capacity to survive, differentiate, proliferate, and to migrate were not different between the
groups. The HiFI led to a decrease in systolic blood pressure (mean change over LoFI: 4.2  2.7 mm Hg), and
increase in plasma nitrite level (mean change over LoFI: 74  32 nM). Applying a mixed-effects linear regres-
sion model, the results demonstrated a significant increase in flow-mediated vasodilation and a decrease in sys-
tolic blood pressure with increasing levels of CD34/KDR-CACs.
Conclusions Sustained improvements in endothelial dysfunction by regular dietary intake of flavanols are associated with mobili-
zation of functional CACs. (Effect of Cocoa Flavanols on Vascular Function in Optimally Treated Coronary Artery Dis-
ease Patients: Interaction Between Endothelial Progenitor Cells, Reactivity of Micro- and Macrocirculation;
NCT00553774). (J Am Coll Cardiol 2010;56:218–24) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.03.039o
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ilavanols, a subgroup of phytochemicals called flavonoids,
ave gained increasing attention, as epidemiological inves-
igations revealed an inverse correlation between the intake
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July 13, 2010:218–24 Flavanols and Circulating Angiogenic Cellsegetables. Several controlled human dietary intervention
tudies that have utilized flavanol-containing foods and bever-
ges in concert with nutrient-matched, low-flavanol controls
ave demonstrated flavanol-dependent effects, including the
ecovery of endothelial function, decreased blood pressure,
nd reductions in platelet aggregation (2). The potential
echanisms of action proposed to underlie the pharmaco-
ogical properties of flavanols are various, and may include
nhanced endothelial homeostatic repair.
Recent studies have demonstrated that bone marrow-
erived circulating angiogenic cells (CACs), also referred to as
arly endothelial progenitor cells (3), contribute to the recovery
nd maintenance of endothelial function (4). Primary and second-
ry preventive life-style interventions and statin therapy can
nhance endogenous endothelial repair mechanisms by stim-
lating CAC mobilization (5). It is unknown whether im-
rovements in cardiovascular function, as previously observed
n flavanol-based dietary interventions, involve CAC-
ependent vascular regenerative processes. In the present study,
e tested, in CAD patients who are medically managed
ccording to currently accepted guidelines, whether a 30-day
ietary intervention with flavanol-containing cocoa leads to an
mprovement of endothelial dysfunction, and whether this
mprovement is associated with an enhanced number and
unction of CACs.
ethods
tudy design. High-flavanol cocoa (HiFI [375 mg cocoa
avanols]) and a matched low-flavanol cocoa (LoFI [9 mg])
ere consumed by CAD patients (Table 1) twice daily over
30-day period, using a randomized, double-masked, cross-
ver study design (Fig. 1) with 1 week of wash-out between
nterventions. Measurements were taken before initiation
day 0, pre-intervention), and the day after completion of
ach intervention (day 30, post-intervention). Pre- and
ost-intervention measurements were taken after overnight
asting and after 30 min of supine rest.
Endothelial vasomotor function assessed as flow-
ediated dilation (FMD), as well as CAC numbers and
unction were defined as primary and secondary outcomes,
espectively. Plasma nitrite and nitrate levels, blood pressure
GE Dinamap, Fairfield, Connecticut), heart rate, and
irculating cytokines involved in CAC mobilization (vascu-
ar endothelial growth factor [VEGF], stromal cell-derived
actor [SDF]-1 , and stem cell factor [SCF]) were mea-
ured as tertiary outcomes.
Inclusion criteria (Fig. 1) comprised a diagnosis of CAD
nd the presence of medical therapy according to American
eart Association/American College of Cardiology (AHA/
CC) secondary prevention guidelines (6). From the 20
atients initially included, 16 patients completed the study
nd were included in data analyses. Randomization and
ocoa drink dispensations were performed by the Depart-
ent of Pharmacology, University of California–San Fran-isco. Patients and investigators were masked throughout hhe study with regard to flavanol
ontent of the test drinks. The
tudy protocol was approved by
he University of California–San
rancisco Committee on Human
esearch, and subjects gave writ-
en informed consent.
lavanol-containing test material.
ocoa drinks (Mars, Inc., McLean,
irginia) were standardized for
avanol content and profile, and
losely matched for macronutrient
ontent, micronutrient content, ca-
oric load, and theobromine and caf-
eine levels. The HiFI was made
ith Cocoapro cocoa powder.
hile minor differences with re-
ard to the content of individual
onstituents cannot be excluded,
he drinks are matched to a de-
ree that reflects the current state
f the art (Table 2). All drinks
ere similar in taste, supplied in
ndividual sachets labeled with a 3-digit code, and prepared
or consumption by mixing with 250 ml skim milk or water.
achets either contained 9 mg (LoFI) or 375 mg (HiFI) of
ocoa flavanols. The amount of flavanols referenced here is
aseline Characteristics of Study PopulationTable 1 Baseline Characteristics of Study Population
Characteristic Value
n (male/female) 16 (13/3)
Age, yrs 64 3
Body mass index, kg/m2 27.8 1.8
Diabetes mellitus 38
Hypertension 88
Hyperlipidemia 94
Prior smoking 63
ACEI/ARB 100
Aspirin* 94
Beta-blocker† 88
Statin‡ 94
Heart rate, beats/min 60 2
Systolic blood pressure, mm Hg 132 2
Diastolic blood pressure, mm Hg 75 2
Total cholesterol, mg/dl 147 8
LDL cholesterol, mg/dl 80 7
HDL cholesterol, mg/dl 46 3
Triglycerides, mg/dl 107 14
Fasting glucose, mg/dl 104 9
White blood cells, per l 5,900 400
hsCRP, mg/l 1.8 0.4
Flow-mediated dilation 4.6 0.3
ata given as n, mean  SEM, or %. *One patient received clopidogrel instead of aspirin because
f a history of gastric ulcers. †Two patients did not receive beta-blockers because of intolerance
nd hypotension. ‡One patient did not receive a statin because of asymptomatically elevated
reatine phosphokinase levels.
Abbreviations
and Acronyms
BA  brachial artery
CAC  circulating
angiogenic cell
CAD  coronary artery
disease
FMD  flow-mediated
dilation
HiFI  high-flavanol
intervention
LDL  low-density
lipoprotein
LoFI  low-flavanol
intervention
NO  nitric oxide
SCF  stem cell factor
SDF  stromal cell-derived
factor
VEGF  vascular
endothelial growth factorACEI  angiotensin-converting enzyme inhibitor; ARB 
igh-density lipoprotein; hsCRP highly sensitive C-reactivangiotensin-receptor blocker; HDL 
e protein; LDL low-density lipoprotein.
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Flavanols and Circulating Angiogenic Cells July 13, 2010:218–24efined as the sum of all monomeric flavanols and their
ligomeric derivatives (2 to 10 monomeric subunits).
MD. Brachial artery (BA) FMD was measured by ultra-
onography (13-MHz transducer, Sonosite Micromax,
othell, Washington) in combination with an automated
nalysis system (Medical Imaging Applications, Iowa City,
owa) in a 21°C temperature-controlled room after 30 min
f supine rest (7). A forearm blood-pressure cuff was placed
istal to the antecubital fossa and inflated to 250 mm Hg for
min. Diameter and Doppler-flow velocity were measured
t baseline and immediately after cuff deflation, at 20, 40,
0, and 80 s. The FMD was expressed as: (diametermax 
Figure 1 Protocol, Inclusion/Exclusion Criteria, and Study Flow
(A) Protocol. (B) Inclusion/exclusion criteria. (C) Study flow diagram. ACEI  angi
College of Cardiology; ARB  angiotensin-receptor blocker; BID  twice a day; BP  b
high-flavanol intervention (375 mg); HR  heart rate; LoFI  low-flavanol intervention (iameterbaseline)/diameterbaseline  100. 0ell assays. The CAC number in whole blood was measured
y flow cytometry as CD34/KDR and CD133/KDR double-
ositive cells in the lymphomononuclear cell gate (8).
Functional CAC characterization was performed after ex
ivo expansion (8). Peripheral blood mononuclear cells were
solated on the basis of the Ficoll method (Vacutainer CPT,
ecton Dickinson, Franklin Lakes, New Jersey) and cul-
ured for 7 days on fibronectin-coated plates. To confirm
he endothelial phenotype and survival, we performed flu-
rescent staining to detect lectin-binding and acetylated
ow-density lipoprotein (LDL) uptake. Chemotaxis toward
VEGF gradient (50 ng/ml in endothelial basal medium-2,
n-converting enzyme inhibitor; AHA/ACC  American Heart Association/American
ressure; CAD  coronary artery disease; GFR  glomerular filtration rate; HiFI 
NYHA  New York Heart Association functional class; PE  physical examination.otensi
lood p
9 mg);.5% bovine serum albumin, Sigma-Aldrich, St. Louis,
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July 13, 2010:218–24 Flavanols and Circulating Angiogenic Cellsissouri) was quantified using a modified Boyden chamber.
he CACs were plated in the upper of 2 chambers
Corning Transwell, Lowell, Massachusetts) and number of
igrated cells counted on the lower side of the dividing
embrane after 6 h. The proliferation fraction was deter-
ined in adherent CACs by immunofluorescent staining
or Ki67. As positive control, VEGF (50 ng/ml) was added
or 3 h to parallel samples.
lasma analyses. Plasma levels of nitrite and nitrate were
easured by Rgp chemiluminescence (7), and SDF-1,
EGF, and SCF were assessed by high-sensitivity enzyme-
inked immunosorbent assay (R&D Systems, Minneapolis,
innesota).
tatistical analysis. Results are expressed as mean SEM.
aseline data represent data of first visit. The primary test
or an effect was 2-way repeated measurements analysis of
ariance (2 factors were drink [HiFI/LoFI] vs. time [pre/
ost]). Analysis of variance and Holm-Sidak post-hoc p
alues were computed with SigmaStat 3.5 software (Systat,
hicago, Illinois). We tested for linear relationships be-
ween CD34/KDR-CAC numbers and FMD using a
andom-effects linear regression model to account for
ithin-person differences, allowing there to be random
ariation in the slopes and intercepts in the association of
ifferent biological outcomes, including CAC number (in-
ependent variable) on FMD (dependent variable) using
tata 9.2 xtmixed procedure (StataCorp, College Station,
exas). All p values and other results reported are for
ooled-effects estimates across individual subjects.
esults
haracteristics of study group. The study group con-
isted of 16 CAD patients having achieved treatment
oals in accordance with current AHA/ACC guidelines
6), as indicated by baseline characteristics and medica-
ion (Table 1). All individual medications and treatment
aradigms, as well as body mass indexes remained unal-
ered throughout the study. The cocoa drinks were well
omposition of Matched Flavanol-Containingest Materials Ingested Twice DailyTable 2 Compo ition of Matched Flavanol-ContainingTest Materials Ingested Twice Daily
Composition LoFI HiFI
Cocoa flavanols, monomers-decamers, mg 9 375
Monomers, mg 3 65
Epicatechin 1 59
Catechin 2 6
Dimers, mg 2 53
Trimers-decamers, mg 3 258
Theobromine, mg 96 93
Caffeine, mg 9 11
Energy, kcal 25 25
Fat, g 0.3 0.4
Carbohydrate, g 4.6 4.3
Protein, g 0.7 0.7
iFI  high-flavanol intervention; LoFI  low-flavanol intervention.olerated, and none of the patients experienced majordverse events, cardiovascular-specific events, or hospi-
alization during the study period.
mprovement of FMD. The average baseline FMD values
ere 4.4 0.5% and 4.6 0.5% (p 0.125) before starting
he LoFI or HiFI regimen, respectively (Fig. 2). By the end
f the 30-day periods, FMD values significantly increased to
.7  0.5% (LoFI) and 8.4  0.8% (HiFI [each p  0.001
s. pre-intervention values]), and the post-HiFI values were
ignificantly greater than post-LoFI values (p  0.001
etween groups). The baseline diameter of the brachial
rtery (LoFI: 5.11  0.30 mm, 4.85  0.33 mm; HiFI:
.43 0.24 mm, 4.86 0.43 mm; p 0.569), the baseline
nd hyperemic blood flow velocities (LoFI: 181  25 cm/s
nd 840  115 cm/s, 210  30 cm/s and 904  79 cm/s;
iFI: 212  34 cm/s and 946  107 cm/s, 165  14 cm/s
nd 862  76 cm/s; p  0.811 and p  0.735), as well
s corresponding blood flow at baseline and at reactive
yperemia (LoFI: 239  43 ml/min and 1,240  228
l/min, 259  34 ml/min and 1,178  79 ml/min; HiFI:
78  34 ml/min and 1,270  142 ml/min, 201  34
l/min and 1,114 191 ml/min; p 0.827 and p 0.929)
ere unaffected by treatments.
obilization of functionally unaltered CACs. After 30-
ay HiFI, CD34/KDR-CACs increased 2.2-fold and
D133/KDR-CACs increased 8.0-fold, relative to
oFI control (each p  0.001) (Fig. 3). Similar to FMD
ffects, CD34/KDR-CACs, but not CD133/KDR-
ACs, were significantly increased after intake of LoFI, as
ompared with baseline.
There was no change throughout the study in cell survival
fter ex vivo expansion as determined by the total number
f cells positive for acetylated LDL uptake and Ulex
uropaeus agglutinin-1 (lectin) binding. Neither the VEGF-
Figure 2 FMD Before and After 30-Day HiFI and LoFI
Flow-mediated vasodilation (FMD) before and after 30-day twice a day HiFI
(375 mg) and LoFI (9 mg). Lines  individual subjects, circles  mean 
SEM. *p  0.05. Abbreviations as in Figure 1.
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Ki67) of ex vivo expanded CACs was significantly altered by
oFI or HiFI consumption. Random cell movement
4.5  1 cells per high-power field) and chemotaxis toward
VEGF gradient (7.1  2.0 cells per high-power field,
52  20%) were not different between the study visits.
We observed no significant changes in plasma VEGF,
DF-1, or SCF and clinical laboratory parameters, includ-
ng C-reactive protein, erythrocyte sedimentation rate, total
holesterol, LDL, high-density lipoprotein, glucose, triglyc-
rides, and blood cell counts.
ncrease in plasma nitrite and decrease in systolic blood
ressure. Levels of plasma nitrite significantly increased
fter HiFI, but remained unaltered after LoFI (Fig. 4).
itrate levels were not significantly affected by either
reatment (average at first visit: 23  5 M).
Arterial blood pressure (BP) was 131 1/76 1 mm Hg
nd 132  1/75  1 mm Hg (p  0.710, p  0.513) at
aseline, respectively. Whereas 30-day LoFI did not signif-
cantly change systolic blood pressure (SBP [129  1 mm
g, p 0.471 vs. day 0]), HiFI significantly decreased SBP
o 125  1 mm Hg (p  0.013 vs. day 0), corresponding to
Figure 3 Mobilization of Functional CACs
Number and function of circulating angiogenic cells (CACs): (A) CD34/KDR; (B)
agglutinin 1 (UEA-1); (D) proliferation; and (E) chemotaxis before and after 1 mo
MNC  mononuclear cells; other abbreviations as in Figure 1.4.2 0.3 mm Hg decrease as compared with LoFI. Mean geart rate and diastolic BP were not significantly affected by
ither treatment.
inear relationship between CD34/KDR-CAC numbers
nd FMD,BAdiameter, and SBP. To assess potential linear
ssociations between CD34/KDR-CAC numbers (inde-
endent variable) and the observed effects (dependent vari-
bles: FMD, BA diameter, SBP, nitrite, and cholesterol),
e performed random-effects linear regression analyses. For
ach 1% increase in CD34/KDR-CAC numbers, there
as a significant increase in FMD of 4.6%, and significant
ecrease in BA diameter and SBP by 0.52 and 4.44 mm Hg,
espectively.
iscussion
hese outcomes demonstrate that a randomized, controlled
ietary flavanol intervention results in improvements in
ndothelial dysfunction and BP, and that this is associated
ith the mobilization of functional CACs in patients with
AD. Despite the fact that our current patient population
as medicated in accordance with current evidence-based
tandards, having reached their BP and LDL treatment
3/KDR; (C) acetylated low-density lipoprotein (acLDL)/Ulex europaeus
twice a day HiFI (375 mg) and LoFI (9 mg). *p  0.05. HPF  high-power field;CD13
nth ofoals, endothelial function was impaired as compared with
a
(
t
t
t
s
C
a
C
t
f
d
s
t
o
i
i
N
w
a
fi
fl
m
c
t
p
s
K
d
p
e
fl
r
c
f
w
O
a
t
w
e
l
A
T
S
n
D
K
R
H
M
d
R
223JACC Vol. 56, No. 3, 2010 Heiss et al.
July 13, 2010:218–24 Flavanols and Circulating Angiogenic Cellsge-matched controls without cardiovascular risk factors
8). Our data demonstrate that a further increase of endo-
helial function can be achieved by complementing standard
reatments with a flavanol-based dietary intervention.
Physiologically, the mobilization of CACs contributes to
he repair response after vascular injury (3,4). We demon-
trated here that a flavanol-rich diet is capable of increasing
AC numbers more than 2-fold, suggesting that the effects
re clinically relevant (3). The effect size observed here for
AC mobilization lies in a range similar to that reported for
reatments with statins, estrogen, and changes in lifestyle
actors, such as exercise and smoking cessation (5). Notably,
uring the course of the present study, our patients did not
how any signs of augmented inflammation, or increases in
he cytokines analyzed (VEGF, SDF-1, and SCF).
A hallmark of endothelial dysfunction is an impairment
f nitric oxide (NO) bioavailability. Corroborating previous
nvestigations in healthy subjects (7,9), we observed an
Figure 4 SBP and Plasma Nitrite
Systolic blood pressure (SBP) and plasma nitrite before and after 30-day twice
a day HiFI (375 mg) and LoFI (9 mg). *p  0.05. Abbreviations as in Figure 1.ncrease in plasma nitrite, which represents both a marker ofO bioavailability and a bioactive NO donor (10). In line
ith previous studies (2), we observed a flavanol intake-
ssociated decrease in SBP, and our data extend these
ndings by showing that SBP-lowering effects of dietary
avanols may complement standard medical BP manage-
ent. While the mechanisms that underlie this effect
annot be ascertained from the present study, it is tenable
hat increased endothelial function and NO bioavailability
lay a causal role in improving arterial blood pressure (10).
Differing in part from Balzer et al. (11), we observed
mall but significant increases in FMD and CD34/
DR-CAC after the LoFI regimen. Based on previous
ata, it seems unlikely that the small flavanol amounts
resent in LoFI would explain our findings, but the pres-
nce in both test drinks of bioactive compounds other than
avanols, for example, methylxanthines, as well as a general
egression to the mean may need to be considered in this
ontext.
Collectively, sustained improvements in endothelial dys-
unction by regular dietary intake of flavanols are associated
ith the mobilization of functional CACs in CAD patients.
ur data support the concept that dietary flavanols, in
ddition to improving cardiovascular functions, can facili-
ate endogenous repair mechanisms that act synergistically
ith current medical therapy. Long-term intervention trials
xamining the effects of high-flavanol diets on cardiovascu-
ar health and function are warranted.
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